Israel's Entera Bio Q3 net loss widens

Entera Bio

14/11/2025 21:16

Overview

Entera Bio reports Q3 2025 net loss of $3.2 mln, with increased operating expenses

Outlook

Cash reserves expected to support operations through mid-2026

Result Drivers

Research and development expenses were $1.6 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024, an increase of $0.1 million.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$3.20 mln
Q3 Operating Expenses
$3.30 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Entera Bio Ltd is $10.00, about 72.6% above its November 13 closing price of $2.74

Press Release: ID:nGNX1cg2VC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)